Outlook Therapeutics Inc (OTLK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 09/30
| 03-2024 | 12-2023 | 09-2023 | 06-2023 | 03-2023 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 47,229 | 10,357 | 23,392 | 33,709 | 43,629 |
| TOTAL | $57,786 | $20,389 | $30,979 | $43,018 | $53,052 |
| Non-Current Assets | |||||
| Investments And Advances | 766 | 797 | 794 | 802 | 810 |
| Other Non-Current Assets | 477 | 499 | 528 | 627 | 162 |
| TOTAL | $1,243 | $1,296 | $1,321 | $1,429 | $972 |
| Total Assets | $59,029 | $21,685 | $32,301 | $44,447 | $54,024 |
| Liabilities | |||||
| Current Liabilities | |||||
| Short Term Debt | N/A | 36,544 | 35,551 | 34,733 | 31,823 |
| Accounts payable and accrued liabilities | 4,363 | 3,480 | 6,575 | 5,055 | 3,620 |
| Accrued Expenses | 3,115 | 4,087 | 2,746 | 8,278 | 6,214 |
| TOTAL | $54,080 | $45,969 | $46,732 | $49,930 | $43,528 |
| Non-Current Liabilities | |||||
| Other Non-Current Liabilities | 139,185 | 60 | 6 | 20 | 8 |
| TOTAL | $139,185 | $60 | $6 | $20 | $8 |
| Total Liabilities | $193,265 | $46,028 | $46,738 | $49,950 | $43,536 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 23,406 | 13,013 | 13,013 | 13,012 | 12,833 |
| Common Shares | 220 | 2,603 | 130 | 2,587 | 2,567 |
| Retained earnings | -593,385 | -479,096 | -467,918 | -454,927 | -434,252 |
| TOTAL | $-134,236 | $-24,343 | $-14,438 | $-5,503 | $10,488 |
| Total Liabilities And Equity | $59,029 | $21,685 | $32,301 | $44,447 | $54,024 |